Skip to search formSkip to main contentSkip to account menu

salmeterol

Known as: Salmaterol, Salmeterolum 
A highly selective, long-acting beta-2 adrenergic agonist with bronchodilatory activity. Salmeterol's benzene moiety resembles the structure of… 
National Institutes of Health

Related topics

Related topics

15 relations
28 ACTUAT salmeterol 0.05 MG/ACTUAT Dry Powder Inhaler [Serevent]Acute DiseaseAdrenergic beta2-Agonists [MoA]Asthma

Narrower (3)

AdvairSalmeterol xinafoateSerevent

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
Effect of β2-adrenergic receptor polymorphism on response to longacting β2 agonist in asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover trial
Highly Cited
2007
Highly Cited
2007
Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial.
Review
2007
Review
2007
Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee
Background: TORCH (Towards a Revolution in COPD Health) is an international multicentre, randomised, placebo-controlled clinical… 
Review
2007
Review
2007
Effect of ADRB2 polymorphisms on response to longacting β2-agonist therapy: a pharmacogenetic analysis of two randomised studies
Highly Cited
2006
Highly Cited
2006
β-Adrenergic Receptor Polymorphisms and Response to Salmeterol
Rationale: Several studies suggest that patients with asthma who are homozygous for arginine at the 16th position of the β2… 
Highly Cited
2006
Highly Cited
2006
Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease.
RATIONALE No currently available treatment is reported to reduce the exaggerated airway wall inflammation of chronic obstructive… 
Highly Cited
2003
Highly Cited
2003
The Efficacy and Safety of Fluticasone Propionate (250 μg)/Salmeterol (50 μg) Combined in the Diskus Inhaler for the Treatment of COPD
Study objectives: To compare the efficacy and safety of the inhaled corticosteroid fluticasone propionate (FP) and the inhaled… 
Review
2000
Review
2000
Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA)
Abstract Objective: To examine the benefits of adding salmeterol compared with increasing dose of inhaled corticosteroids. Design… 
Highly Cited
1997
Highly Cited
1997
Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.
Salmeterol and formoterol are two long-acting beta2-agonists for inhalation, currently being used in clinical practice. The aim… 
Highly Cited
1988
Highly Cited
1988
Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients.
Salmeterol is a new inhaled beta 2 adrenoceptor agonist, which has been shown in animal experiments to produce a more prolonged… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)